Shanghai Pharmaceuticals Holding Co Ltd (601607) Fair Value & Analysis
Healthcare · CN · Market cap 61.9B CNY (≈ $9.2B) · ISIN CNE000000C82
What is Shanghai Pharmaceuticals Holding Co Ltd really worth?
A solid business, trading 51% below our fair value of ¥33.96.
Strengths
Risks
For context
Fair value as of: Aug 20, 2026
From 24 valuation models · updated 16 days ago
Share price +1.0% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price is below even our cautious bear case (¥25.47). The market is more pessimistic than our downside scenario.
- Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.
How to read this chart
60‑month range ¥15.29 – ¥25.03 · fair‑value band ¥25.47 – ¥42.45 · the ¥16.62 price screens below the ¥33.96 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 20, 2026.
Analysis
Shanghai Pharmaceuticals Holding Co Ltd (601607) currently trades at ¥16.62, while our model-based Fair Value estimate is ¥33.96, implying the stock looks roughly 51.1% undervalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of ¥52.08 per share, and 23 of the 24 models we run sit above the ¥16.62 price. Bear case: the Asset-Based group reads lowest at ¥13.71, and 1 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Shanghai Pharmaceuticals Holding Co Ltd generated revenue of 288B CNY at a net margin of 2.0%. Revenue grew 6.4% year over year. It earns a return on equity of 8.1%. Net debt stands at 15.6B CNY. Fundamentals as of Aug 20, 2026
Our scenario range runs from ¥25.47 (bear case) to ¥42.45 (bull case); at ¥16.62, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 16% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 104%, 601607 screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥0.7406 per share, which is 2.2 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: DCF Models (¥52.08) versus Asset-Based (¥13.71). Highest evidence: FCF DCF (76).
Notify me when 601607 reaches fair value
Put 601607 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 52
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others.
Full company description
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric and neurological, tumor, cardiovascular, digestive metabolism, psychoneurotic, neoplasm, respiratory system, and anti-infection diseases, as well as invests in equity. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores. Shanghai Pharmaceuticals Holding Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Pharmaceuticals Holding Co Ltd reported revenue of 284B CNY in FY2025 versus 216B CNY in FY2021, a compound +7.1%/yr. Reported net income was 5.7B CNY in FY2025, compounding +3.0%/yr from FY2021.
of which total revenue +12.0 % · buybacks/dilution −3.3 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch 601607: get an alert when its fair value changes →
Peer Group
Medical Distribution · 78 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $906.77 | $819.31 | −10% |
| Cencora, Inc COR | $330.97 | $211.07 | −36% |
| Cardinal Health, Inc CAH | $234.55 | $141.77 | −40% |
| Henry Schein, Inc HSIC | $88.46 | $71.70 | −19% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Galenica AG GALE | CHF 80.85 | CHF 61.79 | −24% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.03 | ¥28.65 | +36% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 74.40 | kr 28.26 | −62% |
| China National Medicines Corporation 600511 | ¥26.84 | ¥58.22 | +117% |
Compare Shanghai Pharmaceuticals Holding Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Shanghai Pharmaceuticals Holding Co Ltd (601607) overvalued or undervalued?
What is the fair value of 601607?
What is the quality score of 601607?
What is the revenue of Shanghai Pharmaceuticals Holding Co Ltd (601607)?
What is the net profit margin of 601607?
Does Shanghai Pharmaceuticals Holding Co Ltd pay a dividend?
Watch Shanghai Pharmaceuticals Holding Co Ltd in the live analysis
One click puts Shanghai Pharmaceuticals Holding Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.